# A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT05169424** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 9117 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DEVICE:** Trelegy Ellipta
- **DEVICE:** Stiolto Respimat
- **DRUG:** Tiotropium + Olodaterol (5/5 mcg)
- **DRUG:** Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

## Key facts

- **NCT ID:** NCT05169424
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2021-12-27
- **Final completion:** 2021-12-27
- **Target enrollment:** 9117 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169424, "A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05169424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*